Clofazimine (as component of XDR-TB regimen)
Treatment for HIV/AIDS - Extensively drug-resistant Tuberculosis
Typical Dosage: 100mg daily or 300mg three times a week
Effectiveness
65%
Safety Score
62%
Clinical Trials
100
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
62
DangerousModerateSafe
Treatment Details
Dosage Range
100mg daily or 300mg three times a week
Time to Effect
Contributes to regimen effect over months
Treatment Duration
Typically 18-24 months (as part of regimen)
Evidence Quality
MODERATENumber Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$800
Monitoring:$500
Side Effect Mgmt:$1,000
Total Annual:$2,300
Clofazimine (as component of XDR-TB regimen) Outcomes
for HIV/AIDS - Extensively drug-resistant Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+65%
Common Side Effects
Skin discoloration (reddish-brown to black)
+90%
Ichthyosis/dry skin
+50%
Gastrointestinal issues (abdominal pain, nausea, diarrhea)
+30%
QT prolongation
+3%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov